Canada Markets open in 4 hrs 45 mins
  • S&P/TSX

    21,058.18
    -147.02 (-0.69%)
     
  • S&P 500

    4,482.73
    -50.03 (-1.10%)
     
  • DOW

    34,715.39
    -313.21 (-0.89%)
     
  • CAD/USD

    0.7980
    -0.0020 (-0.2474%)
     
  • CRUDE OIL

    83.72
    -1.83 (-2.14%)
     
  • BTC-CAD

    48,916.96
    -4,027.30 (-7.61%)
     
  • CMC Crypto 200

    924.04
    -71.22 (-7.16%)
     
  • GOLD FUTURES

    1,831.80
    -10.80 (-0.59%)
     
  • RUSSELL 2000

    2,024.04
    -38.74 (-1.88%)
     
  • 10-Yr Bond

    1.8330
    0.0000 (0.00%)
     
  • NASDAQ futures

    14,779.50
    -61.50 (-0.41%)
     
  • VOLATILITY

    26.33
    +2.48 (+10.40%)
     
  • FTSE

    7,513.95
    -71.06 (-0.94%)
     
  • NIKKEI 225

    27,522.26
    -250.64 (-0.90%)
     
  • CAD/EUR

    0.7031
    -0.0036 (-0.51%)
     

Monthly information on share capital and company voting rights

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • CLLS
  • CMVLF

(Article 223-16 of General Regulation of the French financial markets authority)

NEW YORK, Dec. 06, 2021 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

Date

Total number of shares
in the capital

Total number of voting
rights

11/30/2021

45,477,810

51,079,282

About Cellectis
Cellectis is a gene editing company, developing first of its kind therapeutic products. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 21 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs.

As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing lifesaving UCART product candidates for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM). .HEAL is a new platform focusing on hemopoietic stem cells to treat blood disorders, immunodeficiencies and lysosomial storage diseases.

Cellectis headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).

For more information, visit www.cellectis.com
Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.

For further information, please contact:

Media contacts:
Pascalyne Wilson, Director, Communications, +33776991433, media@cellectis.com

Investor Relation contact:
Arthur Stril, Chief Business Officer, +33684439609, investors@cellectis.com

Sandya von der Weid, Associate Director, LifeSci Advisors, +41786800538, svonderweid@lifesciadvisors.com

Attachment


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting